{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T23:11:34Z","timestamp":1768000294360,"version":"3.49.0"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,11,1]]},"abstract":"<jats:sec>\n            <jats:title>Abstract:<\/jats:title>\n            <jats:p>Coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide (E\/C\/F\/TAF) has high efficacy and improved renal and bone safety in multiple phase 3 trials; TAF single agent is being studied in 2 phase 3 trials in patients with chronic hepatitis B. We report the results of an open-label, noncomparative switch study evaluating the efficacy and safety of E\/C\/F\/TAF in HIV\/hepatitis B virus (HBV)\u2013coinfected adults. At 48 weeks, 91.7% of the 72 participants maintained or achieved virologic suppression (HIV-1 RNA &lt;50 copies\/mL; HBV DNA &lt;29 IU\/mL). Seroconversion occurred in 2.9% of hepatitis B surface antigen\u2013positive participants and in 3.3% of HBV e antigen\u2013positive participants; 40% of those with abnormal alanine aminotransferase normalized. E\/C\/F\/TAF was associated with improved renal function and reduced bone turnover. These data support the use of E\/C\/F\/TAF in treating HIV\/HBV coinfection.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/qai.0000000000001069","type":"journal-article","created":{"date-parts":[[2016,5,12]],"date-time":"2016-05-12T07:24:35Z","timestamp":1463037875000},"page":"294-298","source":"Crossref","is-referenced-by-count":62,"title":["Brief Report: Efficacy and Safety of Switching to a Single-Tablet Regimen of Elvitegravir\/Cobicistat\/Emtricitabine\/Tenofovir Alafenamide in HIV-1\/Hepatitis B\u2013Coinfected Adults"],"prefix":"10.1097","volume":"73","author":[{"given":"Joel","family":"Gallant","sequence":"first","affiliation":[{"name":"Southwest CARE Center, Santa Fe, NM;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason","family":"Brunetta","sequence":"additional","affiliation":[{"name":"Family and Community Medicine, University of Toronto, Ontario, Canada;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gordon","family":"Crofoot","sequence":"additional","affiliation":[{"name":"Crofoot Research Center, Houston, TX;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Benson","sequence":"additional","affiliation":[{"name":"Be Well Medical Center, Berkley, MI;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony","family":"Mills","sequence":"additional","affiliation":[{"name":"Southern California Men's Medical Group, Los Angeles, CA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cynthia","family":"Brinson","sequence":"additional","affiliation":[{"name":"Central Texas Clinical Research, Austin, TX;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichi","family":"Oka","sequence":"additional","affiliation":[{"name":"AIDS Clinical Center, National Center for Global Health and Medicine, Tokyo, Japan; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Cheng","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc., Foster City, CA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Will","family":"Garner","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc., Foster City, CA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marshall","family":"Fordyce","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc., Foster City, CA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moupali","family":"Das","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc., Foster City, CA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott","family":"McCallister","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc., Foster City, CA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"the GS-US-292-1249 Study Investigators","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R2-20230926","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1001\/jama.2014.8722","article-title":"Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel","volume":"312","author":"Huldrych","year":"2014","journal-title":"JAMA"},{"key":"R4-20230926","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1053\/j.ajkd.2011.01.022","article-title":"Tenofovir-associated kidney toxicity in HIV-infected patients: a review of the evidence","volume":"57","author":"Hall","year":"2011","journal-title":"Am J Kidney Dis."},{"key":"R5-20230926","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1089\/apc.2007.0052","article-title":"Tenofovir-associated Fanconi syndrome: review of the FDA adverse event reporting system","volume":"22","author":"Gupta","year":"2008","journal-title":"AIDS Patient Care and STDS."},{"key":"R6-20230926","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/QAI.0b013e3181dd911e","article-title":"Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir\/lamivudine versus tenofovir\/emtricitabine, administered with efavirenz, in antiretroviral-naive, hiv-1-infected adults: 48-week results from the ASSERT Study","volume":"55","author":"Post","year":"2010","journal-title":"J Acquir Immune Defic Syndr."},{"key":"R7-20230926","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1086\/656417","article-title":"Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study","volume":"51","author":"Stellbrink","year":"2010","journal-title":"Clin Infect Dis."},{"key":"R8-20230926","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1002\/phar.1257","article-title":"Bone health and human immunodeficiency virus infection","volume":"33","author":"Schafer","year":"2013","journal-title":"Pharmacotherapy"},{"key":"R9-20230926","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1093\/infdis\/jir188","article-title":"Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202","volume":"203","author":"McComsey","year":"2011","journal-title":"J Infect Dis."},{"key":"R10-20230926","doi-asserted-by":"crossref","first-page":"3144","DOI":"10.1128\/AAC.00350-08","article-title":"Chronic administration of tenofovir to rhesus macaques from infancy through adulthood and pregnancy: summary of pharmacokinetics and biological and virological effects","volume":"52","author":"Van Rompay","year":"2008","journal-title":"Antimicrob Agents Chemother."},{"key":"R11-20230926","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1016\/S0140-6736(15)60616-X","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials","volume":"385","author":"Sax","year":"2015","journal-title":"Lancet"},{"key":"R12-20230926","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1473-3099(15)00348-5","article-title":"Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study","volume":"16","author":"Mills","year":"2015","journal-title":"Lancet"},{"key":"R13-20230926","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1097\/QAI.0000000000000908","article-title":"Switching to tenofovir alafenamide, coformulated with elvitegravir, cobicistat, and emtricitabine, in HIV-infected patients with renal impairment: 48 week results from a single-arm, multi-center, open-label, Phase 3 study","volume":"71","author":"Pozniak","year":"2015","journal-title":"J Acquir Immune Defic Syndr."},{"key":"R15-20230926","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.jhep.2014.10.035","article-title":"Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection","volume":"62","author":"Agarwal","year":"2015","journal-title":"J Hepatol."},{"key":"R16-20230926","doi-asserted-by":"crossref","first-page":"3563","DOI":"10.1128\/AAC.00128-15","article-title":"Implications of efficient hepatic delivery by tenofovir alafenamide (GS-7340) for hepatitis B virus therapy","volume":"59","author":"Murakami","year":"2015","journal-title":"Antimicrob Agents Chemother."},{"issue":"1 pt 1","key":"R18-20230926","first-page":"15","article-title":"Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C","volume":"20","year":"1994","journal-title":"Hepatology"},{"key":"R19-20230926","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1053\/j.gastro.2013.12.028","article-title":"Randomized comparison of tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B","volume":"146","author":"Fung","year":"2014","journal-title":"Gastroenterology"},{"key":"R20-20230926","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1056\/NEJMoa0802878","article-title":"Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B","volume":"359","author":"Marcellin","year":"2008","journal-title":"N Engl J Med"},{"key":"R21-20230926","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/QAD.0b013e328340fde2","article-title":"Clinical and virological outcomes in HIV-infected patients with chronic hepatitis B on long-term nucleos(t)ide analogues","volume":"25","author":"Martin-Carbonero","year":"2011","journal-title":"AIDS"}],"container-title":["JAIDS Journal of Acquired Immune Deficiency Syndromes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00126334-201611010-00009","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T17:45:22Z","timestamp":1695750322000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00126334-201611010-00009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,1]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/qai.0000000000001069","relation":{},"ISSN":["1525-4135"],"issn-type":[{"value":"1525-4135","type":"print"}],"subject":[],"published":{"date-parts":[[2016,11,1]]}}}